Comparison of PFS and safety for Asian compared to North American and European populations in the phase III trial of pazopanib versus sunitinib in patients with treatment-naive RCC (COMPARZ)

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2013
This article has no abstract
Epistemonikos ID: 8f08e46aa11d8ac51497159b19afef63254cff63
First added on: Feb 05, 2025